"This is a big deal," says Boris Jordan, founder and executive chairman of the board of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), referring to the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administration (DEA) regarding the rescheduling of cannabis.
In a candid conversation with Maureen Meehan, cannabis editor of Benzinga, Jordan delved deep into his perspectives on the monumental news, the implications for the cannabis industry and the role politics might play in the months ahead.
If you are interested in hearing more about these topics, the upcoming Benzinga Cannabis Capital Conference in Chicago is honored to have Jordan as a keynote speaker. Mark your calendar for September 27 – 28.
Biden, DEA & Cannabis: Jordan Spells On Legalization's Future
"We've been expecting this for some time," Jordan begins, recollecting the last significant rally in the cannabis markets when President Joe Biden voiced his support for a re-evaluation of the status of cannabis.
Jordan acknowledges …